Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines

• Published in: Virology journal Vol. 20; no. 1; pp. 64 - 17
• Main Authors: Guo, Xiao, Liu, Dongying, Huang, Yukai, Deng, Youcai, Wang, Ying, Mao, Jingrui, Zhou, Yuancheng, Xiong, Yongai, Gao, Xinghong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07-04-2023; BioMed Central; BMC
• Subjects: Care and treatment; Clinical research advances; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 Vaccines; Efficiency; Epidemics; Health aspects; Humans; Immune system; Immunomodulation; Medical research; Medicine, Experimental; Messenger RNA; mRNA; mRNA Vaccines; Mutation; Non-replicating mRNA vaccines; Optimization; Proteins; Review; RNA, Messenger - genetics; Severe acute respiratory syndrome coronavirus 2; Vaccination; Vaccine development; Vaccine structure; Vaccines, Synthetic - genetics; Vectors (Biology); Viral disease; Viral diseases; Viral infections; Viral Vaccines - genetics; Virus Diseases; China; Non-replicating mRNA vaccines; Clinical research advances; Vaccine structure; Viral disease
• ISSN: 1743-422X; 1743-422X
• DOI: 10.1186/s12985-023-02023-0

The mRNA vaccine technology was developed rapidly during the global pandemic of COVID-19. The crucial role of the COVID-19 mRNA vaccine in preventing viral infection also have been beneficial to the exploration and application of other viral mRNA vaccines, especially for non-replication structure mRNA vaccines of viral disease with outstanding research results. Therefore, this review pays attention to the existing mRNA vaccines, which are of great value for candidates for clinical applications in viral diseases. We provide an overview of the optimization of the mRNA vaccine development process as well as the good immune efficacy and safety shown in clinical studies. In addition, we also provide a brief description of the important role of mRNA immunomodulators in the treatment of viral diseases. After that, it will provide a good reference or strategy for research on mRNA vaccines used in clinical medicine with more stable structures, higher translation efficiency, better immune efficacy and safety, shorter production time, and lower production costs than conditional vaccines to be used as preventive or therapeutic strategy for the control of viral diseases in the future.